Le Lézard
Classified in: Business, Covid-19 virus
Subject: DIV

Stellus Capital Investment Corporation Announces Transition of Dividend from Quarterly to Monthly and Declares First Quarter 2021 Regular Dividend of $0.25 Per Share, in the Aggregate


HOUSTON, Jan. 19, 2021 /PRNewswire/ -- Stellus Capital Investment Corporation (the "Company") (NYSE: SCM) announced today that it will change its dividend payment schedule from quarterly to monthly beginning with the month ended January 31, 2021.  Additionally, the Company announced that its Board of Directors has declared a monthly dividend of $0.0833 per share for each of the months of January, February and March which, in the aggregate, is $0.25 per share for the first quarter.

"I am pleased to announce that we are changing the frequency of our dividend payments from quarterly to monthly. This decision is based on the Company's strong liquidity, stable asset quality and belief that the impact of the COVID-19 pandemic is materially behind it," said Robert T. Ladd, Chief Executive Officer of Stellus Capital Investment Corporation.

Summary of First Quarter 2021 Regular Monthly Dividends

Declared

Ex-Dividend Date

Record Date

Payment Date

Amount per Share

1/15/21

1/28/21

1/29/21

2/16/21

$0.0833

1/15/21

2/25/21

2/26/21

3/15/21

$0.0833

1/15/21

3/30/21

3/31/21

4/15/21

$0.0833

About Stellus Capital Investment Corporation

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940. The Company's investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien, second lien, unitranche and mezzanine debt financing, and corresponding equity investments. The Company's investment activities are managed by its investment adviser, Stellus Capital Management. To learn more about Stellus Capital Investment Corporation, visit www.stelluscapital.com under the "Public Investors" link.

FORWARD-LOOKING STATEMENTS

Statements included herein may contain "forward-looking statements" which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Capital Investment Corporation
W. Todd Huskinson, (713) 292-5414
Chief Financial Officer
[email protected]

SOURCE Stellus Capital Investment Corporation


These press releases may also interest you

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. . Shareholders who purchased shares of AMPL during...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...



News published on and distributed by: